Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri(®)): a prospective, 6-months, open label, observational, non-interventional study

BACKGROUND: Epoprostenol AS (Veletri(®)), a thermostable epoprostenol formulation, provides better drug stability and improved clinical use compared to previous epoprostenol formulations. This study aims to expand clinical experience in the use of Veletri(®), especially regarding tolerability, safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Degering, Julia, Egenlauf, Benjamin, Harutyunova, Satenik, Benjamin, Nicola, Salkić, Amina, Xanthouli, Panagiota, Eichstaedt, Christina A., Seeger, Rebekka, Sitbon, Olivier, Grünig, Ekkehard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847036/
https://www.ncbi.nlm.nih.gov/pubmed/36653855
http://dx.doi.org/10.1186/s12931-022-02296-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847036/
https://www.ncbi.nlm.nih.gov/pubmed/36653855
http://dx.doi.org/10.1186/s12931-022-02296-z

Ejemplares similares